KHKelsey A. Haugh

Kelsey A. Haugh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kelsey A. Haugh has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    In vivo gene editing of human hematopoietic stem and progenitor cells using envelope-engineered virus-like particles

    by Vladimir V. Botchkarev, Sean Harrington, Matteo Stoppato, Alexander Justen, Casey Kimber, Anjali Kapuria, Keylie M. Gibson, Chi-Shuen Chu, Yuanxin Xu, Kelsey Haugh, et al.

    Engineered virus-like particles (VLPs) are a promising technology for in vivo gene editing of human hematopoietic stem and progenitor cells (HSPCs). Here we design and test two different VLP envelopes for human HSPC editing in vitro and in vivo. The first is an optimized version of the baboon envelope BaEVTR, which efficiently transduces human HSPCs in vitro. We show that the optimized BaEVTR VLP enables in vivo editing of β2 microglobulin in long-term human HSPCs (31% at 8 weeks after dosing) and editing of two hemoglobinopathy-relevant loci, BCL11A and HBG1/2 (26% and 7.5%, respectively, at 5 days after dosing), inducing fetal hemoglobin. Our second VLP design uses a CD133-targeted envelope designed to reduce the transduction of mature blood cells and achieves higher in vivo specificity for HSPCs compared to the optimized BaEVTR VLP. As avoiding delivery in filter organs such as the liver would enhance efficiency and safety, we also demonstrate that both VLPs avoid human hepatocytes in a humanized liver model.


  • Open Access

    In vivo imaging of retrovirus infection reveals a role for Siglec-1/CD169 in multiple routes of transmission

    by Kelsey A Haugh, Mark S Ladinsky, Irfan Ullah, Helen M Stone, Ruoxi Pi, Alexandre Gilardet, Michael W Grunst, Priti Kumar, Pamela J Bjorkman, Walther Mothes, et al.

    Early events in retrovirus transmission are determined by interactions between incoming viruses and frontline cells near entry sites. Despite their importance for retroviral pathogenesis, very little is known about these events. We developed a bioluminescence imaging (BLI)-guided multiscale imaging approach to study these events in vivo. Engineered murine leukemia reporter viruses allowed us to monitor individual stages of retrovirus life cycle including virus particle flow, virus entry into cells, infection and spread for retroorbital, subcutaneous, and oral routes. BLI permitted temporal tracking of orally administered retroviruses along the gastrointestinal tract as they traversed the lumen through Peyer’s patches to reach the draining mesenteric sac. Importantly, capture and acquisition of lymph-, blood-, and milk-borne retroviruses spanning three routes was promoted by a common host factor, the I-type lectin CD169, expressed on sentinel macrophages. These results highlight how retroviruses co-opt the immune surveillance function of tissue-resident sentinel macrophages for establishing infection.


  • Open Access

    In vivo imaging of retrovirus infection reveals a role for Siglec-1/CD169 in multiple routes of transmission

    by Kelsey A. Haugh, Mark S. Ladinsky, Irfan Ullah, Ruoxi Pi, Alexandre Gilardet, Priti Kumar, Pamela J. Bjorkman, Walther Mothes, Pradeep D. Uchil

    Early events in retrovirus transmission are determined by interactions between incoming viruses and frontline cells near entry sites. Despite their importance for retroviral pathogenesis, very little is known about these events. We developed a bioluminescence imaging (BLI)-guided multiscale imaging approach to study these events in vivo . Engineered murine leukemia reporter viruses allowed us to monitor individual stages of the retrovirus life cycle including virus particle flow, virus entry into cells, infection and spread for retroorbital, subcutaneous and oral routes. BLI permitted temporal tracking of orally administered retroviruses along the gastrointestinal tract as they traversed the lumen through Peyer’s Patch to reach the draining mesenteric sac. Importantly, capture and acquisition of lymph-, blood- and milk-borne retroviruses spanning three routes, was promoted by a common host factor, the I-type lectin CD169, expressed on sentinel macrophages. These results highlight how retroviruses co-opt the immune surveillance function of tissue resident sentinel macrophages for establishing infection.


  • Open Access

    Longitudinal bioluminescent imaging of HIV-1 infection during antiretroviral therapy and treatment interruption in humanized mice

    by John D. Ventura, Jagadish Beloor, Edward Allen, Tongyu Zhang, Kelsey A. Haugh, Pradeep D. Uchil, Christina Ochsenbauer, Collin Kieffer, Priti Kumar, Thomas J. Hope, et al.

    Non-invasive bioluminescent imaging (NIBLI) of HIV-1 infection dynamics allows for real-time monitoring of viral spread and the localization of infected cell populations in living animals. In this report, we describe full-length replication-competent GFP and Nanoluciferase (Nluc) expressing HIV-1 reporter viruses from two clinical transmitted / founder (T/F) stains: TRJO.c and Q23.BG505. By infecting humanized mice with these HIV-1 T/F reporter viruses, we were able to directly monitor longitudinal viral spread at whole-animal resolution via NIBLI at a sensitivity of as few as 30–50 infected cells. Bioluminescent signal strongly correlated with HIV-1 infection and responded proportionally to virus suppression in vivo in animals treated daily with a combination antiretroviral therapy (cART) regimen. Longitudinal NIBLI following cART withdrawal visualized tissue-sites that harbored virus during infection recrudescence. Notably, we observed rebounding infection in the same lymphoid tissues where infection was first observed prior to ART treatment. Our work demonstrates the utility of our system for studying in vivo viral infection dynamics and identifying infected tissue regions for subsequent analyses. Non-invasive bioluminescent imaging (NIBLI) in small animals allows for in vivo longitudinal imaging of infection spread and pathogenesis. We have taken advantage of the small luciferase reporter protein, Nanoluciferase (Nluc), to generate a replication-competent HIV-1 reporter virus to allow for NIBLI of viral infection in humanize mice. NIBLI via Nluc enabled us to directly visualize longitudinal spreading patterns before, during, and after interruption of daily doses of combined antiretroviral therapy (cART). We observed that rebounding infection often emerged in tissue regions originally associated with infected cells prior to cART treatment. Thus, Nluc-based NIBLI of HIV-1 infection can be used as an experimental tool to study events involved in viral dissemination and spread from initial sites of infection to draining lymphoid tissues before and after cART suppression, as well as locate infected tissues for subsequent cellular characterization of HIV-1 infected cells.


  • A Biocontainment Procedure for Intravital Microscopy of High-Risk Pathogens

    by Kelsey A. Haugh, Ruoxi Pi, Benjamin Fontes, Walther Mothes, Pradeep D. Uchil

    Intravital multiphoton microscopy offers valuable spatio-temporal insight into studies of pathogen-host interactions. Although well established for studies with low-risk biohazard studies, the complexity of the intravital imaging technique has been difficult for applications using high-risk pathogens. Here, we delineate our standard operating procedure (SOP) for intravital microscopy studies of Risk Groups 2 and 3 pathogens. Using carefully designed protocols adapted to the pathogens under study, we present strategies that allow application of this complex technique to high-risk studies while maximizing protection of personnel and animals in the facility. While we describe our SOP for studies of HIV in vivo, these strategies serve as a guideline for designing SOPs for a wide variety of pathogen studies employing intravital imaging.


  • Open Access

    The interferon-inducible antiviral protein Daxx is not essential for interferon-mediated protection against avian sarcoma virus

    by Kelsey A Haugh, Natalia Shalginskikh, Shoko Nogusa, Anna Marie Skalka, Richard A Katz, Siddharth Balachandran

    The antiviral protein Daxx acts as a restriction factor of avian sarcoma virus (ASV; Retroviridae) in mammalian cells by promoting epigenetic silencing of integrated proviral DNA. Although Daxx is encoded by a type I (α/β) interferon-stimulated gene, the requirement for Daxx in the interferon anti-retroviral response has not been elucidated. In this report, we describe the results of experiments designed to investigate the role of Daxx in the type I interferon-induced anti-ASV response.